ClinicalTrials.gg
CompletedNCT00424177Updated Jul 30, 2013Results posted

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

A Phase 2 interventional study of eltrombopag in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-30.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: PurpuraReclassifiedWhy we changed it
Registry
Purpura — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's title name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Purpura.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
15th of 36
66 · median 40
Started
2007
with 2 others
Phase 2
15 of 36
2 open now
Registered
4th of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 15th largest by enrollment, is one of 3 that started in 2007, is one of 15 in phase 2, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts.

For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

Keywords

  • idiopathic thrombocytopenic purpura
  • ITP
  • thrombocytopenia
  • platelets
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 66 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrolment in the study must meet all of the following criteria:

  • Subject has signed and dated a written inform consent.
  • Adults (≥18 years) diagnosed with chronic ITP according to the American Society of Hematology/British Committee for Standards in Hematology guidelines, and a count between ≥20 Gi/L and ≤50 Gi/L on Day 1 (or within 24 hours prior to dosing on Day 1). In addition, a peripheral blood smear should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia (e.g. pseudothrombocytopenia, myelodysplasia). The physical examination should not suggest any disease which may cause thrombocytopenia other than ITP.
  • Subjects who have previously received one or more prior ITP therapies. Previous treatments for ITP include but are not limited to , immunoglobulins, azathioprine, danazol, cyclophosphamide and/or rituximab.
  • Subjects must have either initially responded (platelet count >100 Gi/L) to a previous ITP therapy or have had a bone marrow consistent with ITP within 3 years to rule out myelodysplastic syndromes or other causes of thrombocytopenia.
  • It is important to clearly differentiate the effect of eltrombopag on platelet count from the treatment effects of prior and concomitant ITP therapies. Therefore:

    1. Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 1 week prior to randomization and the platelet count must show a clear downward trend after the last treatment with immunoglobulins. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to randomization, or clearly be ineffective.
    2. Subjects treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for a least 4 weeks prior to randomization. Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to randomization.
  • and activated partial thromboplastin time must be within 80 to 120% of normal range with no history of hypercoagulable state.
  • A complete blood count (CBC), within the reference range (including differential not indicative of a disorder other than ITP), with the following exceptions:
  • Platelet count between ≥20 Gi/L and ≤50 Gi/L on Day 1 (or within 24 hours of Day 1) is required for inclusion.
  • : Subjects with hemoglobin levels between 10g/dL (100g/L) and the lower limit of normal are eligible for inclusion, if anemia is clearly attributable to ITP (excessive blood loss).
  • (ANC ) >1500/mL (1.5 x 10\^9/L) is required for inclusion (elevated White Blood Cells/ANC above the reference range due to steroid treatment is acceptable).
  • The following clinical chemistries MUST NOT exceed the normal reference range by more than 20%: creatinine, , Aspartate aminotransferase, total , total albumin and alkaline phosphatase.
  • Subject is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must either be of non- (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or >1 year), or of childbearing potential and use of one of the following acceptable methods of contraception from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:

Complete abstinence from intercourse; Intrauterine device (IUD); Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide); Male partner is sterile prior to entry into the study and is the only partner of the female; Systemic contraceptives (combined or progesterone only).

  • Subject is able to understand and comply with protocol requirements and instructions and intends to complete the study as planned.

Exclusion criteria

Exclusion Criteria:

A subject will NOT be eligible for inclusion in this study if any of the following criteria apply:

  • Any abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another primary diagnosis (e.g., thrombocytopenia is secondary to another disease).
  • Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  • Any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), AND ≥ two of the following risk factors: hormone replacement therapy, systemic (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, Antithrombin III deficiency, etc), or any other family history of arterial or venous thrombosis.
  • Pre-existing cardiovascular disease (congestive heart failure, Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a >450 msec.
  • Female subjects who are nursing or pregnant (positive serum or urine b-human chorionic gonadotrophin pregnancy test) at screening or pre-dose on Day 1.
  • History of alcohol/drug abuse.
  • Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • Subject treated with drugs that affect function (including but not limited to aspirin, clopidogrel and/or Non Steroidal Anti Inflammatory Drugs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study.
  • History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.
  • All subjects with secondary immune thrombocytopenia, including those with laboratory or clinical evidence of (HIV) infection, anti-phospholipid antibody syndrome, chronic infection, virus infection, or any evidence for active hepatitis at the time of subject screening. If a potential subject has no clinical history that would support HIV infection or hepatitis infection, no further laboratory screening is necessary; however, standard medical practice would suggest further evaluation of patients who have risk factors for these infections.
  • Previous participation in a clinical study with eltrombopag.
  • Subjects planning to have cataract surgery.
  • In France, a subject is neither affiliated with nor a beneficiary of a social security category.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    eltrombopag

    Drug: eltrombopag

Interventions

07

What researchers measure

Primary outcomes

  1. Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1

    Complete blood count, platelet count by blood draw

    Time frame: Day 42 of each cycle

Secondary outcomes

  1. Number of Participants Who Responded (Platelet Count Greater Than or Equal to 50 Gi/L and at Least 2x Baseline) for at Least 80 Percent of Their On-therapy Assessments During Weeks 2-6.

    CBC, platelet counts

    Time frame: Up to 42 days of dosing

  2. Changes in Participants' Platelet Counts During 3 Cycles of Treatment

    Changes from baseline, during on-therapy periods of a cycle, during off-therapy periods of a cycle, and within 4 weeks of permanent discontinuation of eltrombopag treatment.

    Time frame: Up to 1 year

  3. Number of Participants Who Required Rescue Medication

    New idiopathic thrombocytopenic purpura (ITP) medication, increase dose of a concomitant ITP medication from baseline, platelet transfusion, and/or splenectomy

    Time frame: Up to 3 cycles of treatment including follow-up visits following last dose of eltrombopag

  4. Change in Participants Anti-platelet Antibody Levels From Baseline Through Follow-up

    Change in participants' anti-platelet antibody levels was measured as the number of samples positive for at least 1 glycoprotein from baseline to follow-up. Serum glycoprotein-specific antigens: GPIIb/IIIa, Ib/IX, and Ia/IIa

    Time frame: Up to 1 year

  5. Number of Participants With the Indicated Bleeding Signs and Symptoms Using the World Health Organization Bleeding Scale

    World health Organization (WHO) Bleeding Scale Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross blood loss, Grade 4 = debilitating blood loss.

    Time frame: Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)

  6. Number of Participants With the Indicated Bleeding Signs and Symptoms Using the ITP Bleeding Score

    ITP Bleeding Score: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = severe bleeding

    Time frame: Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)

08

Results

Posted Aug 11, 2009

Participant flow

Cycle 1: Eltrombopag 50 mg Starting Dose
Participant flow — Cycle 1: Eltrombopag 50 mg Starting Dose
MilestoneTreatment Period
Started66
Completed55
Not completed11
Withdrew: Lack of efficacy8
Withdrew: Adverse event1
Withdrew: Prolonged response1
Withdrew: Relocation1
Cycle 2: Eltrombopag 50 or 75 mg
Participant flow — Cycle 2: Eltrombopag 50 or 75 mg
MilestoneTreatment Period
Started55
Completed51
Not completed4
Withdrew: Lack of efficacy2
Withdrew: Prolonged response1
Withdrew: Withdrawal by subject1
Cycle 3: Eltrombopag 50 or 75 mg
Participant flow — Cycle 3: Eltrombopag 50 or 75 mg
MilestoneTreatment Period
Started51
Completed48
Not completed3
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1

Complete blood count, platelet count by blood draw

Time frame:
Day 42 of each cycle
Reported as:
Number · participants
Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1
participantsCycle 1Cycle 2Cycle 3
Responders524138
Non-responders01011
Statistical analysis
  • Cycle 2 vs Cycle 3 · Proportion of subjects in cycle 2 or 3: 0.87 · 95% CI 0.74 to 0.94
SecondaryNumber of Participants Who Responded (Platelet Count Greater Than or Equal to 50 Gi/L and at Least 2x Baseline) for at Least 80 Percent of Their On-therapy Assessments During Weeks 2-6.

CBC, platelet counts

Time frame:
Up to 42 days of dosing
Reported as:
Number · participants
Number of Participants Who Responded (Platelet Count Greater Than or Equal to 50 Gi/L and at Least 2x Baseline) for at Least 80 Percent of Their On-therapy Assessments During Weeks 2-6.
participantsCycle 1Cycle 2Cycle 3
At least 80 percent of assessments met criteria383530
Less than 80 percent of assessments met criteria101013
SecondaryChanges in Participants' Platelet Counts During 3 Cycles of Treatment

Changes from baseline, during on-therapy periods of a cycle, during off-therapy periods of a cycle, and within 4 weeks of permanent discontinuation of eltrombopag treatment.

Time frame:
Up to 1 year
Reported as:
Median · Gi/L
Changes in Participants' Platelet Counts During 3 Cycles of Treatment
Gi/LCycle 1Cycle 2Cycle 3
Baseline platelet count33.0 (7.0 to 82.0)25.0 (0 to 66.0)26.0 (8.0 to 167.0)
Highest on-therapy platelet count200.5 (52.0 to 762.0)196.0 (31.0 to 613.0)174.0 (10.0 to 366.0)
Lowest on-therapy platelet count72.0 (6.0 to 354.0)67.5 (7.0 to 454.0)59.0 (2.0 to 344.0)
Highest off-therapy platelet count118.5 (0 to 662.0)92.5 (12.0 to 701.0)125.0 (21.0 to 594.0)
Lowest off-therapy platelet count21.0 (0 to 59.0)22.5 (8.0 to 75.0)22.0 (0 to 187.0)
SecondaryNumber of Participants Who Required Rescue Medication

New idiopathic thrombocytopenic purpura (ITP) medication, increase dose of a concomitant ITP medication from baseline, platelet transfusion, and/or splenectomy

Time frame:
Up to 3 cycles of treatment including follow-up visits following last dose of eltrombopag
Reported as:
Number · participants
Number of Participants Who Required Rescue Medication
participantsCycle 1Cycle 2Cycle 3
Participants who required rescue treatment2210
Participants who did not require rescue treatment645341
SecondaryChange in Participants Anti-platelet Antibody Levels From Baseline Through Follow-up

Change in participants' anti-platelet antibody levels was measured as the number of samples positive for at least 1 glycoprotein from baseline to follow-up. Serum glycoprotein-specific antigens: GPIIb/IIIa, Ib/IX, and Ia/IIa

Time frame:
Up to 1 year
Reported as:
Number · participants
Change in Participants Anti-platelet Antibody Levels From Baseline Through Follow-up
participantsOverall Study
Baseline12
Cycle 2 on-therapy6
Cycle 3 on-therapy7
4-week follow-up8
3-month follow-up1
6-month follow-up3
SecondaryNumber of Participants With the Indicated Bleeding Signs and Symptoms Using the World Health Organization Bleeding Scale

World health Organization (WHO) Bleeding Scale Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross blood loss, Grade 4 = debilitating blood loss.

Time frame:
Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)
Reported as:
Number · participants
Number of Participants With the Indicated Bleeding Signs and Symptoms Using the World Health Organization Bleeding Scale
participantsCycle 1Cycle 2Cycle 3
On-therapy, Week 0 (Day 1), n525249
On-therapy, Week 0, Grade 0262132
On-therapy, Week 0, Grades 1-4263117
On-therapy, Week 0, Grades 2-410106
On-therapy, Week 1 (Day 8), n515149
On-therapy, Week 1, Grade 0343637
On-therapy, Week 1, Grades 1-4171512
On-therapy, Week 1, Grades 2-4423
On-therapy, Week 2 (Day 15), n474543
On-therapy, Week 2, Grade 0353832
On-therapy, Week 2, Grades 1-412711
On-therapy, Week 2, Grades 2-4424
On-therapy, Week 3 (Day 22), n333233
On-therapy, Week 3, Grade 0282526
On-therapy, Week 3, Grades 1-4577
On-therapy, Week 3, Grades 2-4322
On-therapy, Week 4 (Day 29), n312829
On-therapy, Week 4, Grade 0232224
On-therapy, Week 4, Grade 1-4865
On-therapy, Week 4, Grade 2-4220
On-therapy, Week 5 (Day 36), n282629
On-therapy, Week 5, Grade 0242024
On-therapy, Week 5, Grades 1-4465
On-therapy, Week 5, Grades 2-4131
On-therapy, Week 6 (Day 43), n252627
On-therapy, Week 6, Grade 0222222
On-therapy, Week 6, Grades 1-4345
On-therapy, Week 6, Grades 2-4041
Off-therapy, Week 1 (Day 8), n474546
Off-therapy, Week 1, Grade 0373542
Off-therapy, Week 1, Grades 1-410104
Off-therapy, Week 1, Grades 2-4440
Off-therapy, Week 2 (Day 15), n373545
Off-therapy, Week 2, Grade 0262530
Off-therapy, Week 2, Grades 1-4111015
Off-therapy, Week 2, Grades 2-4232
Off-therapy, Week 3 (Day 22), n283046
Off-therapy, Week 3, Grade 0181930
Off-therapy, Week 3, Grades 1-4101116
Off-therapy, Week 3, Grades 2-4247
Off-therapy, Week 4 (Day 29), n71248
Off-therapy, Week 4, Grade 05930
Off-therapy, Week 4, Grades 1-42318
Off-therapy, Week 4, Grades 2-4126
SecondaryNumber of Participants With the Indicated Bleeding Signs and Symptoms Using the ITP Bleeding Score

ITP Bleeding Score: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = severe bleeding

Time frame:
Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)
Reported as:
Number · participants
Number of Participants With the Indicated Bleeding Signs and Symptoms Using the ITP Bleeding Score
participantsCycle 1Cycle 2Cycle 3
Skin, petechiae, on-therapy, Week 0 (Day 1), n505249
Skin, petechiae, on-therapy, Week 0, Grade 0353539
Skin, petechiae, on-therapy, Week 0, Grade 1141710
Skin, petechiae, on-therapy, Week 0, Grade 2100
Skin, petechiae, on-therapy, Week 1 (Day 8), n515148
Skin, petechiae, on-therapy, Week 1, Grade 0414644
Skin, petechiae, on-therapy, Week 1, Grade 11033
Skin, petechiae, on-therapy, Week 1, Grade 2021
Skin, petechiae, on-therapy, Week 2 (Day 15), n474542
Skin, petechiae, on-therapy, Week 2, Grade 0404339
Skin, petechiae, on-therapy, Week 2, Grade 1722
Skin, petechiae, on-therapy, Week 2, Grade 2001
Skin, petechiae, on-therapy, Week 3 (Day 22), n333233
Skin, petechiae, on-therapy, Week 3, Grade 0312832
Skin, petechiae, on-therapy, Week 3, Grade 1241
Skin, petechiae, on-therapy, Week 3, Grade 2000
Skin, petechiae, on-therapy, Week 4 (Day 29), n312829
Skin, petechiae, on-therapy, Week 4, Grade 0302428
Skin, petechiae, on-therapy, Week 4, Grade 1141
Skin, petechiae, on-therapy, Week 4, Grade 2000
Skin, petechiae, on-therapy, Week 5 (Day 36), n282629
Skin, petechiae, on-therapy, Week 5, Grade 0272129
Skin, petechiae, on-therapy, Week 5, Grade 1150
Skin, petechiae, on-therapy, Week 5, Grade 2000
Skin, petechiae, on-therapy, Week 6 (Day 43), n242527
Skin, petechiae, on-therapy, Week 6, Grade 0242327
Skin, petechiae, on-therapy, Week 6, Grade 1020
Skin, petechiae, on-therapy, Week 6, Grade 2000
Skin, petechiae, off-therapy, Week 1 (Day 8), n474548
Skin, petechiae, off-therapy, Week 1, Grade 0453945
Skin, petechiae, off-therapy, Week 1, Grade 1263
Skin, petechiae, off-therapy, Week 1, Grade 2000
Skin, petechiae, off-therapy, Week 2 (Day 15), n363545
Skin, petechiae, off-therapy, Week 2, Grade 0313040
Skin, petechiae, off-therapy, Week 2, Grade 1554
Skin, petechiae, off-therapy, Week 2, Grade 2001
Skin, petechiae, off-therapy, Week 3 (Day 22), n293046
Skin, petechiae, off-therapy, Week 3, Grade 0272639
Skin, petechiae, off-therapy, Week 3, Grade 1247
Skin, petechiae, off-therapy, Week 3, Grade 2000
Skin, petechiae, off-therapy, Week 4 (Day 29), n71248
Skin, petechiae, off-therapy, Week 4, Grade 071241
Skin, petechiae, off-therapy, Week 4, Grade 1006
Skin, petechiae, off-therapy, Week 4, Grade 2001
Skin, ecchymosis, on-therapy, Week 0 (Day 1), n505249
Skin, ecchymosis, on-therapy, Week 0, Grade 0312736
Skin, ecchymosis, on-therapy, Week 0, Grade 1162512
Skin, ecchymosis, on-therapy, Week 0, Grade 2301
Skin, ecchymosis, on-therapy, Week 1 (Day 8), n515148
Skin, ecchymosis, on-therapy, Week 1, Grade 0393735
Skin, ecchymosis, on-therapy, Week 1, Grade 1111312
Skin, ecchymosis, on-therapy, Week 1, Grade 2111
Skin, ecchymosis, on-therapy, Week 2 (Day 15), n474542
Skin, ecchymosis, on-therapy, Week 2, Grade 0423832
Skin, ecchymosis, on-therapy, Week 2, Grade 1579
Skin, ecchymosis, on-therapy, Week 2, Grade 2001
Skin, ecchymosis, on-therapy, Week 3 (Day 22), n333233
Skin, ecchymosis, on-therapy, Week 3, Grade 0282429
Skin, ecchymosis, on-therapy, Week 3, Grade 1584
Skin, ecchymosis, on-therapy, Week 3, Grade 2000
Skin, ecchymosis, on-therapy, Week 4 (Day 29), n312829
Skin, ecchymosis, on-therapy, Week 4, Grade 0242425
Skin, ecchymosis, on-therapy, Week 4, Grade 1744
Skin, ecchymosis, on-therapy, Week 4, Grade 2000
Skin, ecchymosis, on-therapy, Week 5 (Day 36), n282629
Skin, ecchymosis, on-therapy, Week 5, Grade 0252325
Skin, ecchymosis, on-therapy, Week 5, Grade 1334
Skin, ecchymosis, on-therapy, Week 5, Grade 2000
Skin, ecchymosis, on-therapy, Week 6 (Day 43), n242527
Skin, ecchymosis, on-therapy, Week 6, Grade 0202225
Skin, ecchymosis, on-therapy, Week 6, Grade 1432
Skin, ecchymosis, on-therapy, Week 6, Grade 2000
Skin, ecchymosis, off-therapy, Week 1 (Day 1), n474548
Skin, ecchymosis, off-therapy, Week 1, Grade 0423843
Skin, ecchymosis, off-therapy, Week 1, Grade 1575
Skin, ecchymosis, off-therapy, Week 1, Grade 2000
Skin, ecchymosis, off-therapy, Week 2 (Day 15), n363545
Skin, ecchymosis, off-therapy, Week 2, Grade 0262436
Skin, ecchymosis, off-therapy, Week 2, Grade 19119
Skin, ecchymosis, off-therapy, Week 2, Grade 2100
Skin, ecchymosis, off-therapy, Week 3 (Day 22), n293046
Skin, ecchymosis, off-therapy, Week 3, Grade 0162031
Skin, ecchymosis, off-therapy, Week 3, Grade 111913
Skin, ecchymosis, off-therapy, Week 3, Grade 2212
Skin, ecchymosis, off-therapy, Week 4 (Day 29), n71248
Skin, ecchymosis, off-therapy, Week 4, Grade 06931
Skin, ecchymosis, off-therapy, Week 4, Grade 10315
Skin, ecchymosis, off-therapy, Week 4, Grade 2102
Oral, on-therapy, Week 0 (Day 1), n505249
Oral, on-therapy, Week 0, Grade 0464646
Oral, on-therapy, Week 0, Grade 1453
Oral, on-therapy, Week 0, Grade 2010
Oral, on-therapy, Week 1 (Day 8), n515148
Oral, on-therapy, Week 1, Grade 0494946
Oral, on-therapy, Week 1, Grade 1222
Oral, on-therapy, Week 1, Grade 2000
Oral, on-therapy, Week 2 (Day 15), n474542
Oral, on-therapy, Week 2, Grade 0464341
Oral, on-therapy, Week 2, Grade 1121
Oral, on-therapy, Week 2, Grade 2000
Oral, on-therapy, Week 3 (Day 22), n333233
Oral, on-therapy, Week 3, Grade 0333031
Oral, on-therapy, Week 3, Grade 1022
Oral, on-therapy, Week 3, Grade 2000
Oral, on-therapy, Week 4 (Day 29), n312829
Oral, on-therapy, Week 4, Grade 0302629
Oral, on-therapy, Week 4, Grade 1120
Oral, on-therapy, Week 4, Grade 2000
Oral, on-therapy, Week 5 (Day 36), n282629
Oral, on-therapy, Week 5, Grade 0272429
Oral, on-therapy, Week 5, Grade 1120
Oral, on-therapy, Week 5, Grade 2000
Oral, on-therapy, Week 6 (Day 43), n242527
Oral, on-therapy, Week 6, Grade 0232326
Oral, on-therapy, Week 6, Grade 1121
Oral, on-therapy, Week 6, Grade 2000
Oral, off-therapy, Week 1 (Day 8), n474548
Oral, off-therapy, Week 1, Grade 0454348
Oral, off-therapy, Week 1, Grade 1220
Oral, off-therapy, Week 1, Grade 2000
Oral, off-therapy, Week 2 (Day 15), n363545
Oral, off-therapy, Week 2, Grade 0363545
Oral, off-therapy, Week 2, Grade 1033
Oral, off-therapy, Week 2, Grade 2000
Oral, off-therapy, Week 3 (Day 22), n293046
Oral, off-therapy, Week 3, Grade 0272941
Oral, off-therapy, Week 3, Grade 1215
Oral, off-therapy, Week 3, Grade 2000
Oral, off-therapy, Week 4 (Day 29), n71248
Oral, off-therapy, Week 4, Grade 071045
Oral, off-therapy, Week 4, Grade 1022
Oral, off-therapy, Week 4, Grade 2000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cycle 1—0/66 (0%)39/66 (59.1%)
Cycle 2—1/55 (1.8%)30/55 (54.5%)
Cycle 3—0/51 (0%)38/51 (74.5%)
More Than 1 to 30 Days After Last Dose—1/66 (1.5%)17/66 (25.8%)
More Than 30 Days After Last Dose—1/66 (1.5%)7/66 (10.6%)
All Cycles—4/66 (6.1%)55/66 (83.3%)
Most frequent serious events
Most frequent serious events
EventCycle 1Cycle 2Cycle 3More Than 1 to 30 Days After Last DoseMore Than 30 Days After Last DoseAll Cycles
PneumoniaInfections and infestations0/661/550/510/660/661/66
Abdominal pain upperGastrointestinal disorders0/660/550/511/660/661/66
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/660/550/511/660/661/66
Ear hemorrhageEar and labyrinth disorders0/660/550/510/661/661/66
Mouth HemorrhageGastrointestinal disorders0/660/550/510/661/661/66
EpistaxisRespiratory, thoracic and mediastinal disorders0/660/550/510/661/661/66
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCycle 1Cycle 2Cycle 3More Than 1 to 30 Days After Last DoseMore Than 30 Days After Last DoseAll Cycles
HeadacheNervous system disorders9/6610/557/515/660/6616/66
NasopharyngitisInfections and infestations5/662/555/513/661/6610/66
FatigueGeneral disorders1/665/557/513/660/6610/66
DiarrhoeaGastrointestinal disorders6/661/553/511/661/668/66
Back painMusculoskeletal and connective tissue disorders3/664/551/510/660/667/66
Upper respiratory tract infectionInfections and infestations2/661/553/513/660/665/66
NauseaGastrointestinal disorders3/663/550/510/660/665/66
VomitingGastrointestinal disorders2/662/551/510/660/665/66
ArthralgiaMusculoskeletal and connective tissue disorders3/661/551/511/660/665/66
Pain in extremityMusculoskeletal and connective tissue disorders3/660/552/510/660/665/66

Baseline characteristics

Age Continuous
Age Continuous(years)Overall Study Population
Mean49.6 ± 14.61
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Population
Female45
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Overall Study Population
White - White/Caucasian/European47
Asian - East Asian10
White - Arabic/North African6
African American/African2
American Indian or Alaska Native1
Baseline Platelet Count
Baseline Platelet Count(participants)Overall Study Population
Less than 20 giga per liter (Gi/L)4
20 Gi/L to 30 Gi/L29
Greater than 30 Gi/L to 50 Gi/L31
Greater than 50 Gi/L2
Baseline Splenectomy Status
Baseline Splenectomy Status(participants)Overall Study Population
Yes20
No46
Use of Idiopathic Thrombocytopenic Purpura Medication at Baseline
Use of Idiopathic Thrombocytopenic Purpura Medication at Baseline(participants)Overall Study Population
Yes22
No44
09

Study locations

3 sites
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Moscow, 125167, Russian Federation
10

References and documents

Publications

  • Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013 Feb;160(4):538-46. doi: 10.1111/bjh.12169. Epub 2012 Dec 24. PubMed 23278590 ↗
  • This study has not been published in the scientific literature.
  • Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. PubMed 23492914 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
Start
Mar 2007
Primary completionActual
Aug 2008
CompletionActual
Nov 2008
Results first posted
Aug 11, 2009
Last update
Jul 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00424177
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Mar 2007
Primary completion
Aug 2008
Completion
Nov 2008
Results posted
Aug 11, 2009
Last update
Jul 30, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion